The launch of emerging therapies will significantly impact the IgAN market. Thus, North America is expected to possess a 40% market share in the IgA nephropathy market in 2023.
According to Future Market Insights, the IgA Nephropathy Market demand is predicted to increase at a 7.5% CAGR from 2023 to 2033. By the year 2033, the global market for IgA Nephropathy is predicted to reach a value of US$ 85 billion. Key factors such as the high frequency of renal illnesses, expanding R&D efforts, increased investments by market participants, and technological breakthroughs are expected to drive market expansion significantly. Furthermore, the growing number of government initiatives to provide various services, such as payment for diagnostic tests, is a major driver projected to increase the market.
Request a Sample to Obtain Analysis and Comprehensive Market Insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16217
The pandemic of COVID-19 has been linked to an increase in hospitalisations and infection hotspots across the country. By June 2021, there were at least three major waves of COVID-19 around the world, putting a significant pressure on hospital resources, particularly labour and the availability of dialysis equipment and supplies. Furthermore, the COVID-19 pandemic has impacted renal disease patients' access to healthcare. Globally, social separation and lockdown were required norms, resulting in the temporary closure of other medical services. Due to the stoppage of non-urgent consultations and testing services during the pandemic, the diagnosis of various kidney disorders was delayed.
On the other hand, rising awareness of IgA Nephropathy is likely to provide up attractive potential for market expansion. In the United States, for example, an estimated 37 million persons suffer kidney disease. High blood pressure and diabetes, as well as heart disease, obesity, and a family history of renal disease, are major risk factors for the condition. Furthermore, North America and Asia Pacific are two significant contributors to the IgA Nephropathy market.
Key Takeaways from the Market Study
“Growing prevalence of kidney related problems along with research and development for manufacturing medication is favoring the growth of IgA Nephropathy market” states a FMI analyst
Last few days to get reports at discounted prices, offer expires soon!
Request Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-16217
Competitive Landscape
Some of the key companies in the IgA Nephropathy market include Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Otsuka Pharmaceutical, and others
· In June 2021, Novartis Pharmaceuticals announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA Nephropathy (IgAN).
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global IgA Nephropathy market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
Key Segments Profiled in the IgA Nephropathy Market Survey
Diagnosis:
Diseases Type:
Systems:
Population Type:
Route of Administration:
Treatment:
End Users:
We Offer tailor-made Solutions to fit Your Requirements, Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-16217
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market.
Jul 03, 2023
Copyright © 2006 - 2023 PRnob Media, UBIC Solutions, LLC. All Rights Reserved.
